Galectin-3和sST2对射血分数保留的心力衰竭患者的诊断价值

卢子瑄; 张倍健; 顼志兵

doi:10.13201/j.issn.1001-1439.2019.03.017

Galectin-3和sST2对射血分数保留的心力衰竭患者的诊断价值

- 1. 上海中医药大学附属第七人民医院急诊科(上海, 200137);
- 2. 复旦大学附属中山医院心内科

详细信息

通讯作者: 顼志兵,E-mail:xzb6160@163.com

中图分类号: R541.6

收稿日期: 2018-11-03

Diagnostic value of galectin-3 and sST2 in patients with heart failure with preserved ejection fraction

- 1. Emergency Department, Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China;
- 2. Department of Cardiology, Zhongshan Hospital, Fudan University

More Information

Corresponding author: XU Zhibing, E-mail: xzb6160@163.com

Received Date: 03 November 2018

摘要

摘要: 目的：探索半乳糖凝集素-3（galectin-3）和可溶性基质溶素-2（sST2）对射血分数保留的心力衰竭（HFpEF）患者的诊断价值。方法：收集2015-12-2017-06收治于上海市第七人民医院心内科的215例HFpEF患者、108例射血分数降低的心力衰竭（HFrEF）患者和50名健康对照者的临床数据，并比较各组血清galectin-3和sST2水平。通过相关性分析和受试者工作特征（ROC）曲线下面积（AUC）明确galectin-3和sST2对HFpEF患者的诊断价值。结果：sST2、galectin-3和氨基末端B型利钠肽前体（NT-proBNP）水平随着射血分数的降低而显着升高。Galectin-3、sST2与NT-proBNP之间呈正相关。与对照组相比，HFpEF组在galectin-3的AUC为0.878，界值为8.47 ng/ml （灵敏度90.7%，特异性74%）；NT-proBNP的AUC为0.926，sST2的AUC为0.664，其最佳界值分别为374.15 pg/ml和53.63 pg/ml。与HFrEF组对比，galectin-3、NT-proBNP和sST2的AUC分别为0.918、0.940和0.755。结论：Galectin-3和sST2是诊断HFpEF的潜在生物标志物。
- 射血分数保留的心力衰竭 /
- 半乳糖凝集素-3 /
- 可溶性基质溶素-2 /
- 诊断价值
Abstract: Objective: To explore the diagnostic value of galectin-3 and sST2 in patients with heart failure with preserved ejection fraction (HFpEF).Method: A total of 215 patients with HFpEF and 108 patients with heart failure with reduced ejection fraction (HFrEF), who were admitted to the Department of Cardiology, Shanghai Seventh People's Hospital from December 2015 to June 2017, were enrolled. 50 health people were recruited as control.We analyzed their clinical data and compared plasma levels of galectin-3 and sST2 in each group.The diagnostic value of galectin-3 and sST2 in patients with HFpEF was clarified by correlation analysis and area under the ROC curve(AUC).Result: The levels of sST2, galectin-3, and NT-proBNP increase significantly with decreasing ejection fraction.Galectin-3 and sST2 are positively correlated with NT-proBNP.Compared with the control group, the AUC of the HFpEF group of galectin-3 is 0.878, the cut-off value is 8.47 ng/ml(sensitivity 90.7%, specificity 74%);the AUC of NT-proBNP is 0.926.The AUC of sST2 is 0.664, and the optimal cutoff values are 374.15 pg/ml and 53.63 pg/ml, respectively.Compared with patients in HFrEF group, the AUC of galectin-3, NT-proBNP, and sST2 curves is 0.918, 0.940, and 0.755, respectively.Conclusion: Galectin-3 and sST2 are potential biomarkers for the diagnosis of HFpEF.
- heart failure with preserved ejection fraction /
- Galectin-3 /
- sST2 /
- diagnostic value

HTML全文

参考文献(20)

[1]	Owan TE, Hodge DO, Herges RM, et al.Trends in prevalence and outcome of heart failure with preserved ejection fraction[J].N Engl J Med, 2006, 355(3):251-259.
[2]	Senni M, Gavazzi A, Oliva F, et al.In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs.worsening) and ejection fraction.Results from IN-HF Outcome Registry[J].Int J Cardiol, 2014, 173(2):163-169.
[3]	Ambrosy AP, Fonarow GC, Butler J, et al.The global health and economic burden of hospitalizations for heart failure:lessons learned from hospitalized heart failure registries[J].J Am Coll Cardiol, 2014, 63(12):1123-1133.
[4]	de Boer RA, Edelmann F, Cohen-Solal A, et al.Galectin-3 in heart failure with preserved ejection fraction[J].Eur J Heart Fail, 2013, 15(10):1095-1101.
[5]	Brouwers FP, de Boer RA, van der Harst P, et al.Incidence and epidemiology of new onset heart failure with preserved vs.reduced ejection fraction in a community-based cohort:11-year follow-up of PREVEND[J].Eur Heart J, 2013, 34(19):1424-1431.
[6]	Edelmann F, Wachter R, Schmidt AG, et al.Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction:the Aldo-DHF randomized controlled trial[J].JAMA, 2013, 309(8):781-791.
[7]	Lund LH, Benson L, Dahlstrom U, et al.Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction[J].JAMA, 2012, 308(20):2108-2117.
[8]	Solomon SD, Zile M, Pieske B, et al.The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction:a phase 2 double-blind randomised controlled trial[J].Lancet, 2012, 380(9851):1387-1395.
[9]	Shah RV, Januzzi JL Jr.Soluble ST2 and galectin-3 in heart failure[J].Clin Lab Med, 2014, 34(1):87-97, vi-vii.
[10]	Sharma UC, Pokharel S, van Brakel TJ, et al.Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction[J].Circulation, 2004, 110(19):3121-3128.
[11]	van der Velde AR, Gullestad L, Ueland T, et al.Prognostic value of changes in galectin-3 levels over time in patients with heart failure:data from CORONA and COACH[J].Circ Heart Fail, 2013, 6(2):219-226.
[12]	Henry-Okafor Q, Collins SP, Jenkins CA, et al.Soluble ST2 as a Diagnostic and Prognostic Marker for Acute Heart Failure Syndromes[J].Open Biomark J, 2012, 2012(5):1-8.
[13]	Bayes-Genis A, de Antonio M, Vila J, et al.Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification:ST2 versus galectin-3[J].J Am Coll Cardiol, 2014, 63(2):158-166.
[14]	Yancy CW, Jessup M, Bozkurt B, et al.2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol, 2013, 62(16):e147-239.
[15]	Ponikowski P, Voors AA, Anker SD, et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC).Developed with the special contribution of the Heart Failure Association(HFA) of the ESC[J].Eur J Heart Fail, 2016, 18(8):891-975.
[16]	Edelmann F, Holzendorf V, Wachter R, et al.Galectin-3 in patients with heart failure with preserved ejection fraction:results from the Aldo-DHF trial[J].Eur J Heart Fail, 2015, 17(2):214-223.
[17]	de Boer RA, Lok DJ, Jaarsma T, et al.Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction[J].Ann Med, 2011, 43(1):60-68.
[18]	Baydemir C, Ural D, Karauzum K, et al.Predictors of Long-Term Mortality and Frequent Re-Hospitalization in Patients with Acute Decompensated Heart Failure and Kidney Dysfunction Treated with Renin-Angiotensin System Blockers[J].Med Sci Monit, 2017, 23:3335-3344.
[19]	Zhang R, Zhang Y, An T, et al.Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure[J].Biomark Med, 2015, 9(5):433-441.
[20]	Meeusen JW, Johnson JN, Gray A, et al.Soluble ST2 and galectin-3 in pediatric patients without heart failure[J].Clin Biochem, 2015, 48(18):1337-1340.